NGS Banner
Contributors

Graham Speight1, Ephrem Chin1, Jacqueline Chan1, Robert Zeillinger2, Nicole Concin3, David Cook1

1Oxford Gene Technology, Oxford, UK; 2Medical University of Vienna, Dept. of Obstetrics and Gynaecology, Vienna, Austria and 3Medical University, Dept. of Gynaecology and Obstetrics, Innsbruck, Austria

 

Introduction

One of the challenges in the treatment of cancer is the high level of genetic complexity and tumour heterogeneity. Detailed information about the genetic profile of each individual tumour can help guide treatment strategies1. Epithelial ovarian cancer (EOC) is the most lethal gynaecological malignancy2 , and the type II tumours accounting for approximately 75% of all EOCs, are nearly always detected in advanced stages. These highly aggressive tumours are characterised by their morphological and molecular homogeneity and often (>80% of cases) contain TP53 mutations. The GANNET53 (Ganetespib in metastatic, p53 mutant, platinum-resistant ovarian cancer) trial started in October 2015 and aims to improve the prognosis and quality of life in platinum-resistant EOC patients (www.gannet53.eu). This European multi-centre clinical trial is currently in stage II during which biomaterials have been collected and analysed using a SureSeq™ hybridisation-based enrichment panel for targeted next-generation sequencing (NGS), to determine the TP53 mutation status of the samples.

Register with us to read the full article

Once you have registered with us for free you will be able to read all our supportive literature, video tutorials and webinars.

CTA Icon

Stay up-to-date with the latest news from OGT, including new products, support resources, and our DNA Dispatch newsletter